$0.00
(0.00%
) Quote details
USD
$0.00
(0.00%
)At Close (As of Nov 28, 2025)
$517.94M
Market Cap
-
P/E Ratio
-22.97
EPS
$25.20
52 Week High
$7.65
52 Week Low
HEALTHCARE
Sector
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Lyell Immunopharma, Inc. is a cutting-edge biopharmaceutical company headquartered in South San Francisco, California, with additional facilities in Seattle and Bothell, Washington. The company specializes in pioneering T-cell reprogramming technologies designed to formulate innovative therapies targeting solid tumors, thereby enhancing the effectiveness and longevity of T-cell treatments. With its proprietary platforms and a strong commitment to meeting significant unmet medical needs in oncology, Lyell is well-positioned to transform cancer treatment and play a critical role in the evolving immuno-oncology sector.
LPTX
KTTA
NVDA
HBI
TLRY
INTC
BITF
IPG
BYND
CLSK
ADAP
ASST
PLUG
SNAP
BIYA
AAL
TSLA
CIFR
MARA
WULF
NIO
F
MTSR
VALE
SOFI
GOOGL
BTBT
ADTX
GRAB
DVLT
PFE
CAN
DNN
IBRX
RIOT
WBD
AG
APLD
GOOG
IREN
RIG
BAC
AMD
SMR
TMC
CDE
PLTR
ITUB
AGNC
T
AMC
VHAI
NVO
MSTR
NFLX
SAND
MSFT
HBAN
HL
SHOT
LPTX
KTTA
NVDA
HBI
TLRY
INTC
BITF
IPG
BYND
CLSK
ADAP
ASST
PLUG
SNAP
BIYA
AAL
TSLA
CIFR
MARA
WULF
NIO
F
MTSR
VALE
SOFI
GOOGL
BTBT
ADTX
GRAB
DVLT
PFE
CAN
DNN
IBRX
RIOT
WBD
AG
APLD
GOOG
IREN
RIG
BAC
AMD
SMR
TMC
CDE
PLTR
ITUB
AGNC
T
AMC
VHAI
NVO
MSTR
NFLX
SAND
MSFT
HBAN
HL
SHOT